Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Assignment history

Inventors

Xiaoying Jin (Genzyme Corp)
Catherine O'Riordan (Genzyme Corp)
Lin Liu (Genzyme Corp)
Kate Zhang (Genzyme Corp)

All inventors were employed by Genzyme Corp, the original assignee, at the time of the patent's filing.

Original assignee

Genzyme Corp. Genzyme Corp is a biotechnology company focused on developing treatments for rare diseases. It was acquired by Sanofi S.A. in 2011 and operates as a subsidiary. It is currently an operating subsidiary of Sanofi S.A.

Assignment timeline

No recorded assignments were found for US patent 12298313 on the USPTO Assignment Center. This indicates that the original assignee, Genzyme Corp, likely still owns the patent. Genzyme Corp was acquired by Sanofi S.A. in 2011, and operates as a subsidiary.

Timeline diagram

timeline
    title Ownership of US12298313
    2016 : Priority date
    2025 : Filed by Genzyme Corp
         : Issued to Genzyme Corp

NPE / troll-pattern signals

Shell-entity transfer — Not present. The patent is still held by Genzyme Corp, an operating company and subsidiary of Sanofi S.A..
Known asserter in the chain — Not present. Genzyme Corp is not a known NPE.
Repeat correspondent across the chain — Not present. There are no recorded assignments to evaluate for recurring correspondents.
Cascading transfers — Not present. There are no recorded assignments.
Pre-litigation transfer — Not present. There are no recorded assignments.
Bankruptcy fire-sale — Not present. Genzyme Corp was acquired by Sanofi S.A., not dissolved or in bankruptcy.
Privateering — Unclear. While Sanofi S.A. is a large operating company, without assignment records or public statements, it's not possible to determine if this patent is involved in any privateering activities.
Defensive aggregator (anti-NPE) — Not present. The patent is held by an operating company, not a defensive aggregator.

Verdict

Insufficient data
There are no recorded assignments for US patent 12298313 in the USPTO Assignment Center. While the original assignee, Genzyme Corp (a Sanofi subsidiary), is an operating company, the absence of assignment records means no definitive conclusions can be drawn regarding NPE patterns.
https://assignmentcenter.uspto.gov/